Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $15.8 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 86.11% to $15.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.8 million, a 86.11% decrease, with the full-year FY2025 number at $16.3 million, down 90.25% from a year prior.
  • Total Non-Current Liabilities hit $15.8 million in Q1 2026 for Atara Biotherapeutics, down from $16.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $259.2 million in Q1 2024 to a low of $15.8 million in Q1 2026.
  • Median Total Non-Current Liabilities over the past 5 years was $175.7 million (2022), compared with a mean of $165.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 35.23% in 2023 and later tumbled 90.25% in 2025.
  • Atara Biotherapeutics' Total Non-Current Liabilities stood at $244.2 million in 2022, then fell by 5.96% to $229.7 million in 2023, then decreased by 27.12% to $167.4 million in 2024, then tumbled by 90.25% to $16.3 million in 2025, then fell by 2.94% to $15.8 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $15.8 million (Q1 2026), $16.3 million (Q4 2025), and $65.0 million (Q3 2025) per Business Quant data.